DDInter927 DDInter1756
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.
Telavancin {u} (Compound) resembles {v} (Compound) Oritavancin
Telavancin {u} (Compound) resembles {v} (Compound) Vancomycin
Telavancin {u} (Compound) is included by {v} (Pharmacologic Class) Lipoglycopeptides
Telavancin {u} (Compound) causes {v} (Side Effect) Abdominal discomfort
Telavancin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Telavancin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Castor oil
Telavancin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loperamide
Telavancin {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Telavancin {u} may lead to a major life threatening interaction when taken with {v} Dolasetron
Telavancin (Compound) resembles Oritavancin (Compound)
Telavancin (Compound) resembles Vancomycin (Compound)
Telavancin (Compound) is included by Lipoglycopeptides (Pharmacologic Class)
Telavancin (Compound) causes Abdominal discomfort (Side Effect)
Telavancin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Telavancin may lead to a major life threatening interaction when taken with Vemurafenib
Telavancin may lead to a major life threatening interaction when taken with Dolasetron